Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pimozide
Drug ID BADD_D01774
Description A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Indications and Usage Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
Marketing Status approved
ATC Code N05AG02
DrugBank ID DB01100
KEGG ID D00560
MeSH ID D010868
PubChem ID 16362
TTD Drug ID D00KHM
NDC Product Code 66577-017; 76438-002; 49884-348; 49884-347; 14474-029
UNII 1HIZ4DL86F
Synonyms Pimozide | Antalon | Orap | Orap forte | R-6238 | R6238
Chemical Information
Molecular Formula C28H29F2N3O
CAS Registry Number 2062-78-4
SMILES C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Endocrine disorder05.09.01.001--Not Available
Eosinophilia01.02.04.001--
Eructation07.01.02.003--
Extrapyramidal disorder17.01.02.007--
Eye disorder06.08.03.001--Not Available
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Generalised tonic-clonic seizure17.12.01.002--Not Available
Gingival hypertrophy07.09.13.008--Not Available
Gynaecomastia05.05.02.003; 21.05.04.003--
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hyperprolactinaemia05.03.01.002--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypertension24.08.02.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypothermia12.05.03.001; 08.05.01.003--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Menstrual disorder21.01.01.004--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene